Q1 EPS Estimates for Alto Neuroscience Lowered by Wedbush

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Equities research analysts at Wedbush dropped their Q1 2025 earnings estimates for shares of Alto Neuroscience in a report issued on Wednesday, October 23rd. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($0.67) for the quarter, down from their prior estimate of ($0.53). Wedbush currently has a "Neutral" rating and a $4.00 target price on the stock. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.63) per share. Wedbush also issued estimates for Alto Neuroscience's Q2 2025 earnings at ($0.69) EPS, Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.78) EPS, FY2026 earnings at ($2.24) EPS, FY2027 earnings at ($2.31) EPS and FY2028 earnings at ($2.61) EPS.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.07.

Several other research firms have also recently weighed in on ANRO. Robert W. Baird lowered their price objective on shares of Alto Neuroscience from $32.00 to $10.00 and set an "outperform" rating for the company in a research report on Wednesday, October 23rd. RODMAN&RENSHAW cut shares of Alto Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 23rd. Rodman & Renshaw cut shares of Alto Neuroscience from a "buy" rating to a "neutral" rating in a research report on Wednesday, October 23rd. Finally, William Blair reiterated an "outperform" rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $24.40.

Alto Neuroscience Stock Down 3.4 %

ANRO stock traded down $0.15 during trading on Monday, hitting $4.22. 714,407 shares of the stock traded hands, compared to its average volume of 357,412. Alto Neuroscience has a one year low of $3.93 and a one year high of $24.00. The company has a 50 day simple moving average of $12.02 and a 200 day simple moving average of $12.33. The company has a current ratio of 19.85, a quick ratio of 19.85 and a debt-to-equity ratio of 0.04.

Institutional Trading of Alto Neuroscience

Institutional investors have recently made changes to their positions in the business. RA Capital Management L.P. acquired a new position in Alto Neuroscience during the first quarter worth $21,267,000. Price T Rowe Associates Inc. MD acquired a new position in Alto Neuroscience during the first quarter worth $9,788,000. Vanguard Group Inc. acquired a new position in Alto Neuroscience during the first quarter worth $8,233,000. Jennison Associates LLC acquired a new position in shares of Alto Neuroscience in the first quarter valued at $7,039,000. Finally, Artal Group S.A. acquired a new position in shares of Alto Neuroscience in the first quarter valued at $5,372,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.